Skip to main content
NASDAQ:CBPO

China Biologic Products Competitors

$119.99
+1.98 (+1.68 %)
(As of 04/20/2021)
Add
Compare
Today's Range
$118.24
$120.05
50-Day Range
$117.88
$119.99
52-Week Range
$99.74
$120.05
Volume24,016 shs
Average Volume148,695 shs
Market Capitalization$4.72 billion
P/E Ratio33.52
Dividend YieldN/A
Beta0.47

Competitors

China Biologic Products (NASDAQ:CBPO) Vs. TECH, ARGX, QGEN, NVAX, RGEN, and NBIX

Should you be buying CBPO stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to China Biologic Products, including Bio-Techne (TECH), argenx (ARGX), QIAGEN (QGEN), Novavax (NVAX), Repligen (RGEN), and Neurocrine Biosciences (NBIX).

China Biologic Products (NASDAQ:CBPO) and Bio-Techne (NASDAQ:TECH) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Volatility & Risk

China Biologic Products has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500.

Insider and Institutional Ownership

34.8% of China Biologic Products shares are owned by institutional investors. Comparatively, 93.8% of Bio-Techne shares are owned by institutional investors. 2.7% of China Biologic Products shares are owned by company insiders. Comparatively, 3.8% of Bio-Techne shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares China Biologic Products and Bio-Techne's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Biologic Products27.43%8.32%7.64%
Bio-Techne32.69%12.20%8.09%

Analyst Recommendations

This is a breakdown of current ratings and price targets for China Biologic Products and Bio-Techne, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Biologic Products0000N/A
Bio-Techne03702.70

Bio-Techne has a consensus target price of $396.1111, suggesting a potential downside of 1.31%. Given Bio-Techne's higher possible upside, analysts clearly believe Bio-Techne is more favorable than China Biologic Products.

Earnings & Valuation

This table compares China Biologic Products and Bio-Techne's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Biologic Products$503.70 million9.38$138.81 million$4.2828.04
Bio-Techne$738.69 million21.13$229.30 million$3.86103.98

Bio-Techne has higher revenue and earnings than China Biologic Products. China Biologic Products is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Summary

Bio-Techne beats China Biologic Products on 12 of the 13 factors compared between the two stocks.

China Biologic Products (NASDAQ:CBPO) and argenx (NASDAQ:ARGX) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Volatility & Risk

China Biologic Products has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, argenx has a beta of 1, indicating that its share price has a similar volatility profile to the S&P 500.

Insider and Institutional Ownership

34.8% of China Biologic Products shares are owned by institutional investors. Comparatively, 54.2% of argenx shares are owned by institutional investors. 2.7% of China Biologic Products shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares China Biologic Products and argenx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Biologic Products27.43%8.32%7.64%
argenxN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and price targets for China Biologic Products and argenx, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Biologic Products0000N/A
argenx071102.61

argenx has a consensus target price of $297.8750, suggesting a potential upside of 9.39%. Given argenx's higher possible upside, analysts clearly believe argenx is more favorable than China Biologic Products.

Earnings & Valuation

This table compares China Biologic Products and argenx's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Biologic Products$503.70 million9.38$138.81 million$4.2828.04
argenx$78.17 million178.72$-182,520,000.00($4.73)-57.57

China Biologic Products has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than China Biologic Products, indicating that it is currently the more affordable of the two stocks.

Summary

China Biologic Products beats argenx on 8 of the 13 factors compared between the two stocks.

China Biologic Products (NASDAQ:CBPO) and QIAGEN (NYSE:QGEN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Earnings & Valuation

This table compares China Biologic Products and QIAGEN's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
China Biologic Products$503.70 million9.38$138.81 million$4.2828.04
QIAGEN$1.53 billion6.99$-41,460,000.00$1.4332.71

China Biologic Products has higher earnings, but lower revenue than QIAGEN. China Biologic Products is trading at a lower price-to-earnings ratio than QIAGEN, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares China Biologic Products and QIAGEN's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
China Biologic Products27.43%8.32%7.64%
QIAGEN11.18%17.51%8.44%

Volatility & Risk

China Biologic Products has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, QIAGEN has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and price targets for China Biologic Products and QIAGEN, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
China Biologic Products0000N/A
QIAGEN05902.64

QIAGEN has a consensus target price of $60.76, suggesting a potential upside of 29.88%. Given QIAGEN's higher possible upside, analysts clearly believe QIAGEN is more favorable than China Biologic Products.

Insider and Institutional Ownership

34.8% of China Biologic Products shares are owned by institutional investors. Comparatively, 43.6% of QIAGEN shares are owned by institutional investors. 2.7% of China Biologic Products shares are owned by company insiders. Comparatively, 9.0% of QIAGEN shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

QIAGEN beats China Biologic Products on 8 of the 13 factors compared between the two stocks.

Novavax (NASDAQ:NVAX) and China Biologic Products (NASDAQ:CBPO) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability.

Earnings and Valuation

This table compares Novavax and China Biologic Products' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novavax$18.66 million522.91$-132,690,000.00($5.80)-22.71
China Biologic Products$503.70 million9.38$138.81 million$4.2828.04

China Biologic Products has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than China Biologic Products, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Novavax and China Biologic Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Novavax-133.10%-1,346.17%-45.85%
China Biologic Products27.43%8.32%7.64%

Risk & Volatility

Novavax has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500. Comparatively, China Biologic Products has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Novavax and China Biologic Products, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Novavax11402.50
China Biologic Products0000N/A

Novavax currently has a consensus price target of $216.3333, suggesting a potential upside of 64.27%. Given Novavax's higher probable upside, equities research analysts plainly believe Novavax is more favorable than China Biologic Products.

Institutional and Insider Ownership

49.9% of Novavax shares are owned by institutional investors. Comparatively, 34.8% of China Biologic Products shares are owned by institutional investors. 3.3% of Novavax shares are owned by insiders. Comparatively, 2.7% of China Biologic Products shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

China Biologic Products beats Novavax on 7 of the 13 factors compared between the two stocks.

Repligen (NASDAQ:RGEN) and China Biologic Products (NASDAQ:CBPO) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability.

Earnings and Valuation

This table compares Repligen and China Biologic Products' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Repligen$270.24 million34.94$21.41 million$1.07160.71
China Biologic Products$503.70 million9.38$138.81 million$4.2828.04

China Biologic Products has higher revenue and earnings than Repligen. China Biologic Products is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Repligen and China Biologic Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Repligen13.40%6.58%5.00%
China Biologic Products27.43%8.32%7.64%

Risk & Volatility

Repligen has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500. Comparatively, China Biologic Products has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Repligen and China Biologic Products, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Repligen00503.00
China Biologic Products0000N/A

Repligen currently has a consensus price target of $222.75, suggesting a potential upside of 29.54%. Given Repligen's higher probable upside, equities research analysts plainly believe Repligen is more favorable than China Biologic Products.

Institutional and Insider Ownership

84.3% of Repligen shares are owned by institutional investors. Comparatively, 34.8% of China Biologic Products shares are owned by institutional investors. 1.7% of Repligen shares are owned by insiders. Comparatively, 2.7% of China Biologic Products shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

China Biologic Products beats Repligen on 7 of the 13 factors compared between the two stocks.

Neurocrine Biosciences (NASDAQ:NBIX) and China Biologic Products (NASDAQ:CBPO) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability.

Earnings and Valuation

This table compares Neurocrine Biosciences and China Biologic Products' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Neurocrine Biosciences$788.10 million11.35$37.01 million$0.39242.56
China Biologic Products$503.70 million9.38$138.81 million$4.2828.04

China Biologic Products has lower revenue, but higher earnings than Neurocrine Biosciences. China Biologic Products is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Neurocrine Biosciences and China Biologic Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Neurocrine Biosciences8.96%18.18%9.50%
China Biologic Products27.43%8.32%7.64%

Risk & Volatility

Neurocrine Biosciences has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, China Biologic Products has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Neurocrine Biosciences and China Biologic Products, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Neurocrine Biosciences071302.65
China Biologic Products0000N/A

Neurocrine Biosciences currently has a consensus price target of $127.8333, suggesting a potential upside of 35.13%. Given Neurocrine Biosciences' higher probable upside, equities research analysts plainly believe Neurocrine Biosciences is more favorable than China Biologic Products.

Institutional and Insider Ownership

95.3% of Neurocrine Biosciences shares are owned by institutional investors. Comparatively, 34.8% of China Biologic Products shares are owned by institutional investors. 4.3% of Neurocrine Biosciences shares are owned by insiders. Comparatively, 2.7% of China Biologic Products shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Neurocrine Biosciences beats China Biologic Products on 10 of the 13 factors compared between the two stocks.


China Biologic Products Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Bio-Techne logo
TECH
Bio-Techne
1.8$401.37+1.3%$15.61 billion$738.69 million64.22
argenx logo
ARGX
argenx
1.1$272.30+4.0%$13.97 billion$78.17 million-57.57News Coverage
QIAGEN logo
QGEN
QIAGEN
1.7$46.78+0.6%$10.67 billion$1.53 billion57.75
Novavax logo
NVAX
Novavax
1.8$131.69+8.1%$9.76 billion$18.66 million-25.23Earnings Announcement
Analyst Report
Analyst Revision
Repligen logo
RGEN
Repligen
1.9$171.96+1.3%$9.44 billion$270.24 million209.71Analyst Report
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$94.60+2.8%$8.94 billion$788.10 million101.72Analyst Report
Unusual Options Activity
CRISPR Therapeutics logo
CRSP
CRISPR Therapeutics
1.7$106.64+5.3%$8.08 billion$289.59 million-32.71Analyst Upgrade
Acceleron Pharma logo
XLRN
Acceleron Pharma
1.6$126.09+2.2%$7.65 billion$73.99 million-48.68
Fate Therapeutics logo
FATE
Fate Therapeutics
1.8$76.70+6.8%$7.21 billion$10.68 million-41.68
Denali Therapeutics logo
DNLI
Denali Therapeutics
1.5$53.90+4.1%$6.53 billion$26.68 million-24.39
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$43.03+2.9%$6.13 billion$195.99 million268.94Earnings Announcement
Analyst Downgrade
Insider Selling
Analyst Revision
News Coverage
Vir Biotechnology logo
VIR
Vir Biotechnology
1.4$42.21+6.3%$5.49 billion$8.09 million-17.89
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$34.54+2.7%$4.85 billion$85.07 million-36.36Analyst Report
Insider Selling
Twist Bioscience logo
TWST
Twist Bioscience
1.6$92.68+4.9%$4.53 billion$90.10 million-24.71Analyst Revision
Gap Up
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$71.92+8.0%$4.50 billion$20,000.00-5.12Earnings Announcement
Analyst Report
Analyst Revision
Kodiak Sciences logo
KOD
Kodiak Sciences
1.7$84.05+4.4%$4.31 billionN/A-36.23Earnings Announcement
Analyst Upgrade
Analyst Revision
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.9$25.82+3.1%$3.95 billionN/A-13.45Analyst Revision
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$27.50+2.0%$3.89 billionN/A-12.91Analyst Report
Gap Up
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$73.10+6.5%$3.59 billionN/A-42.01Analyst Downgrade
News Coverage
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$29.19+5.8%$2.64 billionN/A0.00Earnings Announcement
Vericel logo
VCEL
Vericel
1.1$50.77+5.7%$2.35 billion$117.85 million-5,077,000.00Analyst Report
Insider Selling
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$31.99+3.9%$2.35 billion$50.04 million0.00Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.5$25.55+7.8%$2.28 billionN/A-11.94Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$12.84+6.9%$2.28 billion$48.83 million-16.89
Editas Medicine logo
EDIT
Editas Medicine
1.6$33.22+5.5%$2.25 billion$20.53 million-19.09
NanoString Technologies logo
NSTG
NanoString Technologies
1.7$49.30+1.8%$2.23 billion$125.57 million-28.83Earnings Announcement
Analyst Report
Insider Selling
Gap Up
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
0.9$45.52+0.3%$2.05 billionN/A0.00Insider Selling
bluebird bio logo
BLUE
bluebird bio
1.8$30.32+3.3%$2.05 billion$44.67 million-2.76
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$6.62+4.1%$1.90 billion$31.43 million-4.53
Ocugen logo
OCGN
Ocugen
1.0$8.75+5.9%$1.73 billionN/A-5.91Earnings Announcement
Analyst Upgrade
Insider Selling
Replimune Group logo
REPL
Replimune Group
1.5$35.05+1.0%$1.63 billionN/A-19.80
AlloVir logo
ALVR
AlloVir
1.5$24.00+6.9%$1.56 billionN/A0.00Analyst Report
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$10.85+4.1%$1.56 billion$102.43 million-18.08Analyst Revision
REGENXBIO logo
RGNX
REGENXBIO
1.6$36.14+2.4%$1.54 billion$35.23 million-14.57Analyst Upgrade
News Coverage
Immunovant logo
IMVT
Immunovant
1.6$15.50+5.7%$1.52 billionN/A-12.02Unusual Options Activity
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$67.93+7.9%$1.51 billionN/A-45.90Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Gap Up
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$34.84+2.2%$1.50 billionN/A0.00Earnings Announcement
Analyst Upgrade
News Coverage
Alector logo
ALEC
Alector
1.3$17.00+8.8%$1.36 billion$21.22 million-7.62News Coverage
Translate Bio logo
TBIO
Translate Bio
1.6$17.16+4.7%$1.29 billion$7.80 million-16.04
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$26.75+6.9%$1.27 billion$100.56 million0.00News Coverage
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$14.99+1.8%$1.26 billionN/A-3.24Analyst Report
News Coverage
Curis logo
CRIS
Curis
1.3$13.57+3.7%$1.24 billion$10 million-16.55Earnings Announcement
Analyst Report
Unusual Options Activity
News Coverage
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$15.13+8.2%$1.15 billion$356.07 million7.42Analyst Report
Cortexyme logo
CRTX
Cortexyme
1.1$36.77+6.6%$1.09 billionN/A-15.32Earnings Announcement
Analyst Upgrade
Insider Selling
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$27.50+3.4%$994.46 millionN/A-4.55Earnings Announcement
Insider Selling
Analyst Revision
News Coverage
Vaxcyte logo
PCVX
Vaxcyte
1.7$19.24+0.8%$988.53 millionN/A0.00Earnings Announcement
Scholar Rock logo
SRRK
Scholar Rock
1.5$27.92+1.9%$960.25 million$20.49 million-11.59Earnings Announcement
News Coverage
Gap Up
Sutro Biopharma logo
STRO
Sutro Biopharma
1.5$19.68+4.3%$907.50 million$42.74 million-218.67Analyst Revision
News Coverage
Mesoblast logo
MESO
Mesoblast
1.4$6.99+3.7%$906.88 million$32.16 million-7.94
Passage Bio logo
PASG
Passage Bio
1.8$15.50+1.9%$836.64 millionN/A0.00
This page was last updated on 5/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.